Human platelet-derived growth factor (PDGF) is a connective tissue cell mitogen comprising two related chains encoded by distinct genes. The B chain is the homolog of the v-sis oncogene product. Properties that distinguish these ligands include greater transforming potency of the B chain and more efficient secretion of the A chain. By a strategy involving the generation of PDGF A and B chimeras, these properties were mapped to distinct domains of the respective molecules. Increased transforming efficiency segregated with the ability to activate both alpha and beta PDGF receptors. These findings genetically map PDGF B residues 105 to 144 as responsible for conformational alterations critical to beta PDGF receptor interaction, and provide a mechanistic basis for the greater transforming potency of the PDGF B chain.
Introduction

Results
Strategy for construction of PDGF chimeric molecules
We initially constructed ten chimeric PDGF molecules to investigate structural regions of PDGF A or PDGF B associated with specific PDGF functions (LaRochelle et al. 1990). The chimeric constructs were developed utilizing pre existing, or engineered, common restriction endonuclease sites within the PDGF A-or PDGF B-coding sequences. All PDGF A-or PDGF B-coding sequences altered for this purpose by oligonucleotide-mediated, site-directed mutagenesis (Kunkel, 1985) were first shown to possess biological activities indistinguishable from those of their respective parental cDNAs. Each chimera was designated on the basis of the codon at which the recombination was performed. Four of the chimeric constructs, A 97B " , B98A 98, A 177B179, and B178A 178, were designed to maintain the functional integrity of the PDGF B minimal transforming domain (King et al. 1985; Hannink et al. 1986) or the analogous region of PDGF A (Fig. 1 ). An additional six constructs further dissected the minimal transforming domain. The A 143B145 and b 144A 144 chimeras divided the transforming region roughly in half, while A 104B106 and B105A 105 chimeras as well as A 153B155 and B154A 154 chimeras further subdivided the minimal transforming domains (Fig. 1) .
Mapping of a PDGF B sub-domain responsible for its potent transforming activity
All wild type parental and recombinant PDGF constructs (LaRochelle et al. 1990) were transferred into a vector containing the metallothionein promoter (MMTneo) and analyzed for transforming activity by transfection of NIH/3T3 cells. Since the MMTneo vector also contained a dominant, selectable neomycin marker gene, it was possible to score neomycin-resistant colony formation for each plasmid as well. Thus, we were able to compare precisely the specific transforming efficiencies of each construct.
As shown in Fig. 1 wild type PDGF B construct. In contrast, B98A98 and A 1' 'B 119 chimeric constructs, which possessed the analogous domain of PDGF A, showed ten to twenty fold lower specific transforming efficiency, equivalent to that of PDGF A (Fig. 1) . Chimeras A 104B106, b 144a 144 and b 154A 154 also possessed high specific transforming efficiency, whereas the reciprocal chimeras B105A 105, A 143B145 and A 153B 155, respectively, were only weakly transforming. All of these findings suggested that amino acid residues 105-144 of PDGF B were responsible for its more potent transforming activity (Fig. 1) .
To test this hypothesis, we substituted only the minimal regions mapped above that were responsible for differences in transforming activities of the native PDGF A and B molecules. As shown in Fig. 1 , the AB105-144 chimera possessed high specific transforming activity, indistinguishable from that of PDGF B. Conversely, substitution of PDGF A codons 104-144 for those of PDGF B reduced transforming activity of the resulting chimera to that of the PDGF A molecule. All of these results conclusively demonstrated that the subdomain encompassed by PDGF B amino acid residues 105-144 was responsible for its more potent transforming properties.
Immunochemical characterization of PDGF chimeric proteins
We next sought to verify the chimeric constructs by analysis of their translational products. Thus, each NIH/3T3 transfectant was metabolically labeled and subjected to immunoprécipitation analysis using antisera specific to PDGF A or PDGF B amino or carboxy termini, respectively. As shown in Fig. 2A , the primary PDGF A translational product, p42, as well as its 3 8 x l0 3 and 32x103Mr processed forms, were detected in lysates of PDGF A transfected cells. Similarly, the primary PDGF B translational product, p54, was processed at amino and carboxy termini to 40x103 M r, 3 4 x l0 3Mr and 24x103 Mr species (Fig. 2B) .
A representative chimera, A 143B145, encoded a p45 primary translational product, and was processed at amino and carboxy termini to 40 and 38x103 M r forms, as well as a major 26x103M r species (Fig. 2C) . The reciprocal chimeric construct directed synthesis of a p46 translational product, which was amino terminally processed to a major p32 species (Fig. 2D) levels of PDGF immunoreactive protein. However, only those chimeras which contained PDGF A carboxy terminal amino acid residues 178-211, namely B98A 98, B105A 105, B144A 144, b 154A 154 and B 178A 178, were found to be efficiently secreted. Fig. 3 shows that the B178A 178 chimera, which contained only PDGF A amino acid residues 178-211, was efficiently released, whereas the reciprocal chimera, A 177B179, remained more than 90 % membrane associated. To confirm our immunological findings, we analyzed mitogenic activities associated with culture fluids and crude membrane preparations of transfectants containing parental or chimeric PDGF constructs. Comparable mitogenic activity was detected in each crude membrane fraction. However, only in the case of PDGF A and those chimeras containing at least the carboxy terminal thirty-four amino acid residues of PDGF A, was mitogenic activity detectable in culture fluids (data not shown). In each case, the mitogenic activity was specifically inhibited by neutralizing PDGF antibody, establishing the PDGF-related nature of the secreted mitogen. As shown above, potent transforming activity mapped to PDGF B amino acid residues 105-144 (Fig. 1) . Thus, localization of the domain responsible for differences in PDGF A and B secretory properties to their carboxy terminal regions excluded this property from being responsible for their different transforming activities.
Activation o f alpha and beta PDGF receptors in NIH/3T3 cells expressing PDGF chimeras
We next investigated whether PDGF receptor binding and/or activation might be responsible for the differences in oncogenic potency of PDGF A and B. Thus, we examined the steady state level of tyrosine phosphorylation of alpha and beta receptors expressed in NIH/3T3 transfectants containing either wild type PDGF A or B constructs, as well as each of the chimeras. To do so, cell lysates were enriched for each receptor by immunoprécipitation with alpha or beta PDGF receptor-specific peptide antisera, followed by immunoblotting with antiphosphotyrosine antibody. As shown in Fig. 4 , NIH/3T3 cells showed no detectable alpha or beta PDGF receptor tyrosine phosphorylation. As expected from known receptor binding properties of each ligand (Matsui et al. 1989a,6; Hart et al. 1988; Heldin et al. 1988) , NIH/3T3 cells expressing PDGF A demonstrated tyrosine phosphorylated 1 8 0 xl0 3Mr alpha but not beta receptor species. In contrast, both 1 80 xl0 3Mr alpha and beta receptor species were tyrosine phosphorylated in PDGF B-producing cells (Fig. 4) . The specificity of the antibody was demonstrated by the ability of phosphotyrosine to compete for immunodetection of these proteins (data not shown). When the steady state level of PDGF receptor tyrosine phosphorylation was examined in transfectants containing the PDGF chimeras, readily detectable levels of the activated 180 x 103 Mr alpha PDGF receptor were observed in each case (Fig. 4) . However, there was chronic activation of the 180 x 10s Mr beta PDGF receptor species of cells expressing A9'B 99, A 104B106, b 144a 144 and B154A 154, as well as B178A 178 chimeras, all of which contained at least PDGF B amino acid residues 105-144. As shown in Fig. 4 , the AB105-144 chimera which substituted only PDGF B amino acid residues 105-144 into the analogous region of PDGF A, demonstrated the same pattern of receptor tyrosine phosphorylation as observed with PDGF B. Conversely, the switch of analogous PDGF A amino acid residues into PDGF B led to a pattern of receptor tyrosine phosphorylation indistinguish able from that of PDGF A. These results demonstrate that amino acid residues 105-144 are responsible for the ability of PDGF B to bind and activate preferentially the beta PDGF receptor. Since increased transforming activity of PDGF B molecules mapped to these same residues, we conclude that the ability to activate beta receptors in addition to alpha receptors provides the basis for the . 1989a,b) . Thus, it is possible that in fibroblasts which express both alpha and beta receptors, the alpha receptor may be somewhat less efficient than the beta receptor in stimulating this pathway. Alternatively, non-saturating ligand concentrations expressed in autocrine transformation of NIH/3T3 must be quantitatively more effective in mitogenic signalling when both receptors are stimulated, as opposed to the alpha receptor alone.
We also mapped an additional domain of the two PDGF molecules that was responsible for the differences in their PDGF secretory properties. This domain localized to the carboxy terminal amino acid residues of PDGF, and was demonstrated not to be a determinant of the differences in transforming potency of the two molecules. These differences in the secondary properties could be explained either by a tendency of the PDGF B carboxy terminus to cause association with the cell membrane or an effect of the analogous domain of the PDGF A to promote secretion. Further studies will be necessary to resolve this question.
There is increasing evidence that functional domains of protein correspond to individual exons (Gilbert, 1978; 1985) . In the case of the PDGF A molecule, the signal peptides and proteolytic processing sites correspond to specific exons (Heldin and Westermark, 1989). Amino acid residues 105-144 which specify beta PDGF receptor activation are included exclusively within exon four of PDGF B. In contrast, the secretory properties of the long form of PDGF A or the membrane retention properties of PDGF B correspond to amino acids predominantly encoded by exon 6 of either molecule. Thus, the functional differences which we mapped correspond to individual exons specific for either of the PDGFs.
Comparison 
